Clinical Trials Logo

Chronic Kidney Disease stage4 clinical trials

View clinical trials related to Chronic Kidney Disease stage4.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06394544 Not yet recruiting - Inflammation Clinical Trials

Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment

Start date: August 2024
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effects of Brazil nut supplementation on inflammation, oxidative stress and intestinal microbiota in patients with chronic kidney disease undergoing conservative treatment.

NCT ID: NCT06094920 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Optimize@Home
Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria. The main questions it aims to answer are: - What is the feasibility (and advantages) of remote clinical trial conduct with multiple medications in patients with type 2 diabetes and elevated albuminuria? - What is the individual response to the SGLT2 inhibitor empagliflozin in urine albumin-creatinine ratio? - What is the individual response to the SGLT2 inhibitor empagliflozin in systolic blood pressure, body weight, eGFR, and fasting plasma glucose? - Can suboptimal treatment responses to empagliflozin be overcome by the addition or substitution with finerenone? Participants will collect all study data in the comfort of their own environments - First-morning void urine samples - Capillary blood samples - Blood pressure - Body weight Participants will be assigned to a 3-week treatment period with empagliflozin 10 mg/day. Based on the albuminuria response after 2 weeks, participants will be allocated to one of three treatment regimens after the 3-week treatment period with empagliflozin: - Continue empagliflozin for 4 more weeks (good response). - Continue empagliflozin for 4 more weeks and add finerenone 10 or 20 mg will be added for 4 weeks (moderate response). - Stop empagliflozin and start finerenone 10 or 20 mg for 4 weeks (no response)

NCT ID: NCT04349683 Not yet recruiting - Glomerulonephritis Clinical Trials

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

Start date: April 30, 2020
Phase: Phase 4
Study type: Interventional

This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.

NCT ID: NCT03348839 Not yet recruiting - Kidney Diseases Clinical Trials

Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease

Start date: March 2018
Phase: N/A
Study type: Interventional

This medico-economic research project (PRME) aim to analyse NeLLY service efficiency for not on dialysis severe chronic kidney disease (DFG < 30ml/mn) patients care. NeLLY is a service that includes telemonitoring, educational therapy and support for patients with severe chronic kidney disease.